Literature DB >> 24745674

Epidemiology, prognosis, and risk factors in mastocytosis.

Knut Brockow1.   

Abstract

This article updates current knowledge about epidemiology, prognosis, and risk factors for major complications in mastocytosis. A prevalence of mastocytosis of 1 in 10000 inhabitants has been reported, but underdiagnosis is assumed. The prognosis for cutaneous and indolent systemic mastocytosis is excellent. For more advanced forms of disease, prognostic parameters have been identified. A high extent of skin involvement, increased basal serum tryptase values, and extensive blistering are risk factors for severe mast cell activation episodes in children, whereas these associations seem to be less strong or nonexistent for anaphylaxis and osteoporosis in adult patients with indolent systemic mastocytosis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epidemiology; Mast cell activity syndrome; Mastocytosis; Monoclonal mast cell activation syndrome; Prognosis; Risk factors

Mesh:

Substances:

Year:  2014        PMID: 24745674     DOI: 10.1016/j.iac.2014.01.003

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  24 in total

Review 1.  Mast Cell Activation Syndrome.

Authors:  Marianne Frieri
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

Review 2.  Mast cell activation in the context of elevated basal serum tryptase: genetics and presentations.

Authors:  Paneez Khoury; Jonathan J Lyons
Journal:  Curr Allergy Asthma Rep       Date:  2019-11-27       Impact factor: 4.806

Review 3.  Systemic Mastocytosis: The Difficult Patient with a Rare Disease. Case Presentation and Brief Review.

Authors:  Daniel H Desmond; Mark G Carmichael
Journal:  Hawaii J Med Public Health       Date:  2018-02

Review 4.  Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association.

Authors:  Patrizia Bonadonna; Massimiliano Bonifacio; Carla Lombardo; Roberta Zanotti
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

Review 5.  Endocrine manifestations of systemic mastocytosis in bone.

Authors:  Loren Wissner Greene; Kamyar Asadipooya; Patricia Freitas Corradi; Cem Akin
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 6.  Drugs and Vaccines Hypersensitivity in Children with Mastocytosis.

Authors:  Francesca Mori; Giuseppe Crisafulli; Annamaria Bianchi; Paolo Bottau; Silvia Caimmi; Fabrizio Franceschini; Lucia Liotti; Claudia Paglialunga; Francesca Saretta; Carlo Caffarelli
Journal:  J Clin Med       Date:  2022-06-01       Impact factor: 4.964

Review 7.  Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

Authors:  Molly M Gallogly; Hillard M Lazarus; Brenda W Cooper
Journal:  Ther Adv Hematol       Date:  2017-08-19

8.  [Recurrent skin blisters for more than 7 months in a girl aged 15 months].

Authors:  Ke-Yao Li; Jian-Ping Tang; Xiao-Ting Liang; Zhou-Ying Zhao; Shu-Zhen Yue
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-09

Review 9.  Mastocytosis in Children.

Authors:  Nicholas Klaiber; Santhosh Kumar; Anne-Marie Irani
Journal:  Curr Allergy Asthma Rep       Date:  2017-10-07       Impact factor: 4.806

10.  Safety of COVID-19 Vaccination in Patients with Mastocytosis and Monoclonal Mast Cell Activation Syndrome.

Authors:  Rayan Kaakati; Dilawar Khokhar; Cem Akin
Journal:  J Allergy Clin Immunol Pract       Date:  2021-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.